BioSpace News Archive

Sangamo Therapeutics lost two powerhouse partners Friday after it reported that both Novartis and Biogen discontinued focusing on gene regulation therapies in the neurology space.

As demand for biotech talent increases, the need to offer competitive pay to the average employee puts financial pressure on companies to increase CEO pay as well.

Biomarkers as a surrogate endpoint in ALS will go on trial on March 22 as Biogen and Ionis’s tofersen faces the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee.

Karuna Therapeutics released data Monday from the Phase III EMERGENT-3 trial showing that KarXT met the primary endpoint, significantly improving symptom severity.

Takeda will advance its experimental drug for plaque psoriasis, TAK-279, to Phase III later this year after the TYK2 inhibitor met its primary and secondary endpoints in a Phase IIb study.

DolCas Biotech, LLC and its concentrated turmeric extract, Curcugen®, have been selected by nutritional supplement company, Clear Within, for its vegan nutricosmetic.

Ascidian Therapeutics , a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO).

Covalon Technologies Ltd. today announced its participation in the Synova NICU Leadership Forum from Sunday, March 19 to Thursday, March 23, 2023 in Tuscon, Arizona.

CHARM Therapeutics today announced a strategic discovery collaboration with Bristol Myers Squibb (NYSE: BMY) for the identification and optimisation of compounds against Bristol Myers Squibb selected targets.

Danimer Scientific, Inc. today announced it had closed a new senior secured term loan (“Term Loan”) with an aggregate principal amount of $130 million that expands its capital structure, significantly improves its near-term liquidity position, and enables it to maintain strategic and operational flexibility as it executes its growth strategy.